Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size, Status and Forecast 2021-2027

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
  • 1.2.2 PCR
  • 1.2.3 In-situ Hybridization
  • 1.2.4 Immunohistochemistry
  • 1.2.5 Sequencing
  • 1.2.6 Others
• 1.3 Market by Application
  • 1.3.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share by Application: 2016 VS 2021 VS 2027
  • 1.3.2 Oncology
  • 1.3.3 Neurological Disorders
  • 1.3.4 Cardiovascular Disease
  • 1.3.5 Immunological Disorders
  • 1.3.6 Others
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Perspective (2016-2027)
• 2.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Growth Trends by Regions
  • 2.2.1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Regions: 2016 VS 2021 VS 2027
  • 2.2.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Historic Market Share by Regions (2016-2021)
  • 2.2.3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Regions (2022-2027)
• 2.3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Industry Dynamic
  • 2.3.1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Trends
  • 2.3.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Drivers
  • 2.3.3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Challenges
  • 2.3.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players by Revenue
  • 3.1.1 Global Top Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players by Revenue (2016-2021)
  • 3.1.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Players (2016-2021)
• 3.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue
• 3.4 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Concentration Ratio
  • 3.4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue in 2020
• 3.5 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Key Players Head office and Area Served
• 3.6 Key Players Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Solution and Service
• 3.7 Date of Enter into Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Breakdown Data by Type

• 4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Historic Market Size by Type (2016-2021)
• 4.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Type (2022-2027)

5 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Breakdown Data by Application

• 5.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Historic Market Size by Application (2016-2021)
• 5.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Application (2022-2027)

6 North America

• 6.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2016-2027)
• 6.2 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
  • 6.2.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2021)
  • 6.2.2 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2022-2027)
  • 6.2.3 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2027)
• 6.3 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
  • 6.3.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2021)
  • 6.3.2 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2022-2027)
  • 6.3.3 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2027)
• 6.4 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country
  • 6.4.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2016-2021)
  • 6.4.2 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2022-2027)
  • 6.4.3 United States
  • 6.4.3 Canada

7 Europe

• 7.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2016-2027)
• 7.2 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
  • 7.2.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2021)
  • 7.2.2 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2022-2027)
  • 7.2.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2027)
• 7.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
  • 7.3.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2021)
  • 7.3.2 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2022-2027)
  • 7.3.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2027)
• 7.4 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country
  • 7.4.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2016-2021)
  • 7.4.2 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2022-2027)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic

8 Asia-Pacific

• 8.1 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2016-2027)
• 8.2 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
  • 8.2.1 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2021)
  • 8.2.2 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2022-2027)
  • 8.2.3 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2027)
• 8.3 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
  • 8.3.1 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2021)
  • 8.3.2 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2022-2027)
  • 8.3.3 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2027)
• 8.4 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Region
  • 8.4.1 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Region (2016-2021)
  • 8.4.2 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Region (2022-2027)
  • 8.4.3 China
  • 8.4.4 Japan
  • 8.4.5 South Korea
  • 8.4.6 Southeast Asia
  • 8.4.7 India
  • 8.4.8 Australia

9 Latin America

• 9.1 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2016-2027)
• 9.2 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
  • 9.2.1 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2021)
  • 9.2.2 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2022-2027)
  • 9.2.3 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2027)
• 9.3 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
  • 9.3.1 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2021)
  • 9.3.2 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2022-2027)
  • 9.3.3 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2027)
• 9.4 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country
  • 9.4.1 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2016-2021)
  • 9.4.2 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2022-2027)
  • 9.4.3 Mexico
  • 9.4.4 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2016-2027)
• 10.2 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
  • 10.2.1 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2021)
  • 10.2.2 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2022-2027)
  • 10.2.3 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2027)
• 10.3 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
  • 10.3.1 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2021)
  • 10.3.2 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2022-2027)
  • 10.3.3 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2027)
• 10.4 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country
  • 10.4.1 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2016-2021)
  • 10.4.2 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2022-2027)
  • 10.4.3 Turkey
  • 10.4.4 Saudi Arabia
  • 10.4.5 UAE

11 Key Players Profiles

• 11.1 Qiagen NV
  • 11.1.1 Qiagen NV Company Details
  • 11.1.2 Qiagen NV Business Overview
  • 11.1.3 Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
  • 11.1.4 Qiagen NV Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
  • 11.1.5 Qiagen NV Recent Development
• 11.2 GE Healthcare
  • 11.2.1 GE Healthcare Company Details
  • 11.2.2 GE Healthcare Business Overview
  • 11.2.3 GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
  • 11.2.4 GE Healthcare Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
  • 11.2.5 GE Healthcare Recent Development
• 11.3 Agilent Technologies
  • 11.3.1 Agilent Technologies Company Details
  • 11.3.2 Agilent Technologies Business Overview
  • 11.3.3 Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
  • 11.3.4 Agilent Technologies Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
  • 11.3.5 Agilent Technologies Recent Development
• 11.4 F Hoffman La Roche
  • 11.4.1 F Hoffman La Roche Company Details
  • 11.4.2 F Hoffman La Roche Business Overview
  • 11.4.3 F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
  • 11.4.4 F Hoffman La Roche Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
  • 11.4.5 F Hoffman La Roche Recent Development
• 11.5 Foundation Medicine
  • 11.5.1 Foundation Medicine Company Details
  • 11.5.2 Foundation Medicine Business Overview
  • 11.5.3 Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
  • 11.5.4 Foundation Medicine Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
  • 11.5.5 Foundation Medicine Recent Development
• 11.6 Thermo Fisher Scientific Inc.
  • 11.6.1 Thermo Fisher Scientific Inc. Company Details
  • 11.6.2 Thermo Fisher Scientific Inc. Business Overview
  • 11.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
  • 11.6.4 Thermo Fisher Scientific Inc. Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
  • 11.6.5 Thermo Fisher Scientific Inc. Recent Development
• 11.7 Leica Biosystems Nussloch GmBH
  • 11.7.1 Leica Biosystems Nussloch GmBH Company Details
  • 11.7.2 Leica Biosystems Nussloch GmBH Business Overview
  • 11.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
  • 11.7.4 Leica Biosystems Nussloch GmBH Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
  • 11.7.5 Leica Biosystems Nussloch GmBH Recent Development
• 11.8 Pfizer
  • 11.8.1 Pfizer Company Details
  • 11.8.2 Pfizer Business Overview
  • 11.8.3 Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
  • 11.8.4 Pfizer Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
  • 11.8.5 Pfizer Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer